eli lilly stock retatrutide Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Seeking Differentiation Through a Triple

Eso es lo que no mostraron en la mayora de los reportajes en los medios, a pesar de que es la primera frase del artculo

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas

CONCLUSION In the short to medium term, simple reloadable autoinjectors are a credible option to align environmental sustainability with commercial drivers, in particular the need to scale

[3] GLP-1 Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom (Accessed July August 2025)

In a human study, there was no significant difference observed between the fecal SCFA amounts of those consuming yogurt, fermented milk, and sweetened yogurt